Fc RIIIA and Fc RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab | Zendy

Emanuela Carlotti | Zendy; Giuseppe A. Palumbo | Zendy; Elena Oldani | Zendy; Daniele Tibullo | Zendy; Silvia Salmoiraghi | Zendy; A. Rossi | Zendy; Josée Golay | Zendy; Alessandro Pulsoni | Zendy; R. Foà | Zendy; Alessandro Rambaldi | Zendy

Open Access

Fc RIIIA and Fc RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

Author(s) -

Emanuela Carlotti,

Giuseppe A. Palumbo,

Elena Oldani,

Daniele Tibullo,

Silvia Salmoiraghi,

A. Rossi,

Josée Golay,

Alessandro Pulsoni,

R. Foà,

Alessandro Rambaldi

Publication year - 2007

Publication title -

haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.782

H-Index - 142

eISSN - 1592-8721

pISSN - 0390-6078

DOI - 10.3324/haematol.11288

Subject(s) - rituximab , medicine , follicular lymphoma , lymphoma , chop , oncology , cohort , immunology , gastroenterology

We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research